Wet Macular Degeneration Clinical Trial
— PAMEROfficial title:
Effects of Anti-VEGF Injections (Ranibizumab, Lucentis) on Visual Acuity, Reading Speed and Retinal Thickness in Wet-AMD Patients
Verified date | July 2021 |
Source | Centre Hospitalier Régional Metz-Thionville |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
AMD (age-related macular degeneration), is the leading cause of blindness in individuals over the age of 55. There is no cure for wet-AMD but anti-VEGF treatments significantly minimize the vision loss over time. To study the correlation between anti-VEGF injection bevacizumab (Lucentis), visual acuity, macular thickness and last but not least reading speed in wet-AMD patients. The study was conducted on 50 eyes of 50 wet-AMD patients. Subjects were monthly treated with an intra-vitreal Lucentis injection for 3 months; further injections were given when a loss of 5 or more letters of visual acuity was observed and/or when the retinal thickness in the affected macular area increased by 100 µm. In addition to a full ophthalmological examination reading speed was investigated via the Radner reading chart before and 3 months after treatment. The collected data was analyzed using paired t-tests.
Status | Completed |
Enrollment | 50 |
Est. completion date | August 1, 2013 |
Est. primary completion date | June 1, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - AMD, Age related macular degeneration (Wet-form) Exclusion Criteria: - Age related macular degeneration (Dry-form) - Diabetic macular oedema - Other related macular oedemas |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Régional Metz-Thionville | University of Pecs |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reading speed day 0 | Reading speed measurement via Radner reading chart (a highly standardized multilingual reading test system that was developed for clinical practice and research) We measured reading speed on 50 patients before and 3 months after treatment. The reading chart consists of "sentence optotypes", which are optimized reading test items, standardized by construction and statistical selection. Sentence optotypes consist of short sentences that are highly comparable in terms of number of words (14 words), word length, and position of words, lexical difficulty and syntactical complexity. Language specific characteristics were taken into account as were the number of letters and syllables per word, line, and sentence. The advantage of such sentence optotypes is that they minimize variations between test items and keep the geometric proportions constant. | day 0 | |
Primary | Reading speed M3 | Reading speed measurement via Radner reading chart (a highly standardized multilingual reading test system that was developed for clinical practice and research) We measured reading speed on 50 patients before and 3 months after treatment. The reading chart consists of "sentence optotypes", which are optimized reading test items, standardized by construction and statistical selection. Sentence optotypes consist of short sentences that are highly comparable in terms of number of words (14 words), word length, and position of words, lexical difficulty and syntactical complexity. Language specific characteristics were taken into account as were the number of letters and syllables per word, line, and sentence. The advantage of such sentence optotypes is that they minimize variations between test items and keep the geometric proportions constant. | month 3 | |
Secondary | Visual acuity using the ETDRS chart day 0 | ETDRS stands for the Early Treatment of Diabetic Retinopathy Study. This landmark study helped to define the standardization of eye charts and visual acuity testing, resulting in the development of these ETDRS charts. The charts use ETDRS letters, or a geometric progression in letter size from line to line, each line being of equal difficulty.
The ETDRS chart format has been accepted by the National Eye Institute and the FDA, and is mandated for many clinical trials performed worldwide. It is accepted worldwide as today's Gold Standard for accurate visual acuity measurement. ETDRS scoring can be accomplished in a number of different ways. The most common method is when the patient starts at the top of the chart and begins to read down the chart. The patient reads down the chart until he or she reaches a row where a minimum of three letters on a line cannot be read. The patient is scored by how many letters could be correctly identified. |
day 0 | |
Secondary | Visual acuity using the ETDRS chartM3 | ETDRS stands for the Early Treatment of Diabetic Retinopathy Study. This landmark study helped to define the standardization of eye charts and visual acuity testing, resulting in the development of these ETDRS charts. The charts use ETDRS letters, or a geometric progression in letter size from line to line, each line being of equal difficulty.
The ETDRS chart format has been accepted by the National Eye Institute and the FDA, and is mandated for many clinical trials performed worldwide. It is accepted worldwide as today's Gold Standard for accurate visual acuity measurement. ETDRS scoring can be accomplished in a number of different ways. The most common method is when the patient starts at the top of the chart and begins to read down the chart. The patient reads down the chart until he or she reaches a row where a minimum of three letters on a line cannot be read. The patient is scored by how many letters could be correctly identified. |
month 3 | |
Secondary | Maculare thickness Day0 | Optical coherence tomography (OCT) is a non-invasive imaging test that provides anteroposterior images by measuring the echo time and intensity of reflected or backscattered light from intraretinal microstructures.
With OCT, each of the retina's distinctive layers can be seen, allowing us to map and measure their thickness. |
day 0 | |
Secondary | Maculare thickness M3 | Optical coherence tomography (OCT) is a non-invasive imaging test that provides anteroposterior images by measuring the echo time and intensity of reflected or backscattered light from intraretinal microstructures.
With OCT, each of the retina's distinctive layers can be seen, allowing us to map and measure their thickness. |
Month 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04049266 -
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
|
Phase 2/Phase 3 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT05038371 -
Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
|
||
Completed |
NCT03278262 -
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
|
||
Completed |
NCT00590694 -
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
|
Phase 2/Phase 3 | |
Completed |
NCT04516278 -
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
Completed |
NCT03844074 -
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 3 | |
Recruiting |
NCT05637255 -
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT04756310 -
Study of Nutritional Supplementation in Patients With Unilateral Wet AMD
|
N/A | |
Active, not recruiting |
NCT05112861 -
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
Enrolling by invitation |
NCT03999801 -
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
|
Phase 2 | |
Terminated |
NCT03699618 -
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
|
||
Completed |
NCT01666821 -
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
|
N/A | |
Completed |
NCT03022292 -
The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
|
Phase 4 | |
Completed |
NCT02944227 -
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
|
Phase 4 | |
Terminated |
NCT03452527 -
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT01243086 -
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
|
Phase 2 | |
Completed |
NCT03823300 -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
|
Phase 3 | |
Recruiting |
NCT04420923 -
Optimizing the Treatment Strategy for Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03954626 -
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
|
Phase 3 |